01 — At a Glance
The Youngest Pharma in Top 20. Also the Most Aggressive on Debt.
- 52-Week High / Low₹1,910 / ₹1,097
- Q3 Revenue (Dec 2025)₹807 Cr
- Q3 PAT₹109 Cr
- Q3 EPS₹7.32
- Annualised EPS (Q3×4)₹29.28
- Book Value₹227
- Price to Book5.97x
- EV / EBITDA19.0x
- Debt / Equity0.77x
- Net Debt (Q3)₹2,270 Cr
Auditor’s Opener: ERIS just reported Q3 FY26 consolidated revenue of ₹807 crore (+11% YoY), with 9M revenue of ₹2,373 crore (+10% YoY). Q3 PAT at ₹109 crore, EPS ₹7.32 — but here’s the kicker: management guided FY26 at ₹3,200 crore revenue (+12%) and ₹1,150 crore EBITDA, implying Q4 will be absolutely loaded. Insulin cartridges now at 25% market share (vs 8% at acquisition). Semaglutide partner (Natco) got CDSCO nod. Swiss Parenterals wholly owned as of Jan 2026. And net debt/EBITDA to drop below 1.5x by end of calendar 2026. This is a company eating its vegetables and asking for more.
02 — Introduction
The Pharmacy Kid Who Went Full M&A Junkie
ERIS Lifesciences is the pharmaceutical equivalent of a startup that suddenly discovered private equity’s cheat code: acquire, integrate, extract, repeat. Established 2007. Listed June 2017. At 18 years old, it’s already the youngest company in India’s top 20 pharma by ranking, and it got there by spending ₹6,000 crores in cash on acquisitions in three years.
The business thesis is simple: branded generics in chronic therapies (diabetes, cardiac, dermatology, women’s health). The execution is aggressive: acquired derma brands from Glenmark (₹340 Cr), Dr. Reddy’s (₹275 Cr), Biocon’s nephrology portfolio (₹366 Cr), Biocon’s insulin + oncology + critical care (₹1,242 Cr), Swiss Parenterals for sterile injectables (₹637 Cr + ₹237.5 Cr), Levim Lifetech for GLP-1 capabilities (₹540 Cr), and Chemman Labs for vial manufacturing (₹105 Cr). All in the last 36 months.
The result? A company that was 100% domestic branded formulations in FY22 is now 87% DBF, 13% exports/injectables, with manufacturing footprint across Guwahati, Ahmedabad, Bhopal (under construction), and Swiss facilities in Europe.
Q3 FY26 was the moment where the integration story collided with scaling gravity. Insulin cartridges are winning market share. GLP-1 (semaglutide) is days away from launch. Debt is real. And management’s confidence — borderline reckless, honestly — that they can deliver 12% growth while deleveraging at the same time is making analysts either believers or sceptics. No middle ground.
Concall Highlight (Feb 2026): “We didn’t find the need of putting another team,” on semaglutide field force deployment. Translation: we are doing this with our existing diabetes teams. Lean. Confident. Possibly delusional. Jury’s out.
03 — Business Model: Branded Generics, But Make It Aggressive
DBF Dominance + Injectable Pivot + Data Centre Dreams
ERIS is a branded generics shop. DBF is chronic-therapy focused: 81% chronic, 19% acute. Top therapies: anti-diabetes (32%), cardiac (16%), vitamins (14%), dermatology (13%), women’s health (6%), CNS (5%), super-specialty (9%), other (5%). The company’s original thesis was owning diabetes + cardiac through branded generics — differentiated by being cheaper than innovators but better quality than street generics.
Now? It’s three businesses:
Business 1: DBF (87% of revenue) — Branded generics in India. Doctors prescribe, chemists stock, patients swallow. Margins: 36–37% EBITDA. Growth: 10–12% annually. Consistency: a Swiss watch.
Business 2: Export Injectables (13% of revenue) — Swiss Parenterals manufactures and exports sterile injectables to 70 markets. Margins: 30–35% EBITDA. Timeline: ramping. Headcount: growing.
Business 3: Optionality — GLP-1 (semaglutide/tirzepatide space), data centre immersion cooling fluids (via partnerships), insulin internalization at Bhopal, EU CDMO capabilities in Swiss. These are 3–5 year payback stories. But the bet is that one of them hits $200 million revenue. If it does, multiples re-rate.
Distribution: 4,000+ stockists, 4,858 field forces, 5 lakh+ chemists. Field force size: 3,700+ MRs. Top 5 therapies contribute 80% of DBF revenue. Top 20 mother brands contribute 70%. This is not diffuse. This is concentrated mosaic.
Anti-Diabetes32%DBF Mix
Cardiac16%DBF Mix
Dermatology13%DBF Mix
Vitamins & Others39%DBF Mix
💬 If you owned ERIS stock, what’d excite you more: semaglutide capturing 5% market share, or insulin cartridges hitting 30%? Drop your view.
04 — Financials Overview: Q3 FY26
The Quarter Where Growth Met Gross Margin Reality
Result type: Quarterly Results | Q3 FY26 EPS: ₹7.32 | Annualised EPS (Q3×4): ₹29.28 | 9M FY26 EPS: ₹24.59 (₹368.4 Cr PAT / 14.97 Cr shares)
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 807 | 727 | 792 | +11.0% | +1.9% |
| Operating Profit | 282 | 250 | 288 | +12.8% | -2.1% |
| OPM % | 35% | 34% | 36% | +100 bps | -100 bps |
| PAT | 109 | 87 | 134 | +25.3% | -18.7% |
| EPS (₹) | 7.32 | 5.82 | 8.94 | +25.8% | -18.1% |
Deep Dive on Q3 Weirdness: Revenue up 11% YoY, but PAT up 25%? That’s because Q3 FY25 had ONE-TIME labour code benefit that inflated PAT. Normalize that, and Q3 operating performance is steady: EBITDA ₹286 Cr, margin 35%. The sequential drop from Q2 is merchandise-related (injectables/insulin skew in product mix = lower gross margins currently, expected to normalize as Bhopal internalization kicks in). Interest cost down 15% YoY (from better debt management), tax rate “more than 200 bps lower” per management. This quarter was messy. Next quarter (Q4) should show the payoff, with management guiding ₹3,200 Cr full-year revenue and ₹1,150 Cr EBITDA (vs ₹2,373 Cr + ₹861 Cr in 9M = implying Q4 contributes ~₹827 Cr revenue, ₹289 Cr EBITDA, 35% margin). Do the math yourself. It checks out. Just uncomfortable timing on gross margin.
05 — Valuation: The 42.5x P/E Elephant in the Room
Is This a Discount or a Danger Signal?
Join 10,000+ investors who read this every week.
